The objective for this study is to examine alpha suppression in PTSD and evaluate it as a predictor of treatment outcome. We will first examine if there are differences in alpha suppression PTSD patients (prior to treatment) and the typical…
ID
Source
Brief title
Condition
- Anxiety disorders and symptoms
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
We will first examine differences in the deviant-stimuli induced alpha
suppression between PTSD and controls. We will then see how these differences
in PTSD individuals relate to their treatment outcome.
Secondary outcome
-
Background summary
The mismatch negativity (MMN) is observed following rare or unique sensory
events, and reflects pre-attentional sensory processing of unexpected stimuli.
The MMN is altered in several mental illnesses, including post-traumatic stress
disorder (PTSD), but did not yield consistent result. The Achilles-heal of the
MMN which limits its viability as clinical is that it cannot be reliably
identified within all individuals. We propose to test an alternative EEG
measure to the MMN, oscillatory alpha suppression, in patients with PTSD. Our
previous work in the typical populations has shown alpha suppression to be
reliably indentified within individuals, and correlate with variability in
attentional performance.
Study objective
The objective for this study is to examine alpha suppression in PTSD and
evaluate it as a predictor of treatment outcome. We will first examine if there
are differences in alpha suppression PTSD patients (prior to treatment) and the
typical population. We will then see if these differences can be used as
individualized predictors of treatment outcome.
Study design
a case controlled study, with comparison within PTSD patients and versus
control-subjects.
Study burden and risks
There are no risks for standard perceptual tasks, and EEG recordings are
completely non-invasive.
Meibergdreef 5 Meibergdreef 5
Amsterdam 1105 AZ
NL
Meibergdreef 5 Meibergdreef 5
Amsterdam 1105 AZ
NL
Listed location countries
Age
Inclusion criteria
Patients:
- Patients with a diagnosis of chronic PTSD with symptom duration > 3 months
- CAPS score of * 45
- Male and female, aged 18 years and above
- Written informed consent
- Eligible for exposure therapy;Controls:
- Meeting the stressor A criterion of DSM-IV PTSD
- Male and female, aged 18 years and above
- Written informed consent
Exclusion criteria
Patienten:
- Suicidal risk
- Presence of any of the following DSM IV diagnoses: psychotic disorder incl. schizophrenia, a bipolar disorder, depression with psychotic features, or excessive substance related disorder.
- Primary diagnosis of severe depressive disorder
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL39956.018.12 |